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In Uganda most cancers to the exception of bladder and penis are increasing in incidence. The 
incidence of cancer of stomach is 5.6/100,000 from 0.8/100,000 in the 1960s a seven fold 
increase.The purpose of this guideline document is to highlight the salient points in gastric 
cancer diagnosis and treatment in the Ugandan context. It doesn’t only outline what is practical 
and efficacious but also our aspirations of practice as resources committed to the whole area of 
Oncological care services improve in the country. The primary and secondary prevention 
strategies are outlined. The multistage process of gastric oncogenesis is discussed in relation to 
the scientific basis of diagnostic and screening procedures. The treatment modalities including 
surgery radiotherapy and chemotherapy are discussed. A prognostication scale is included.  
Traditionally gastric cancer presents late and with a poor prognosis. The greatest strategy we 
have for management is in primary and secondary prevention. However a better understanding 
of how it arises (risk factors) will be important in informing prevention and treatment strategies. 
The Uganda cancer-working group intends that this information is disseminated to wider 
readership in the region as part of the strategy of improving Oncological care service in the 
region. 
Introduction   
 
This document contains information about the epidemiology, presentation, investigations, and 
treatment for early and late disease complications of treatment as well as prognosis. Whereas 
over the past several decades gastric cancer as dropped in incidence globally1, in Uganda most 
including gastric cancers have increased in incidence to the exception of bladder and penis 
cancer. This coincides with marked social and lifestyle changes and with the emergence of 
AIDS epidemic. The incidence of cancer of stomach is 5.6/100,000 from 0.8/100,000 in the 
1960’s, a seven-fold increase2.  
 
Gastric cancer traditionally carries a poor prognosis because it presents at an advanced stage of 
the disease. If diagnosed at an early stage, it is a curable disease. Strategies to improve outcomes 
are: to promote primary prevention strategies of eradication of Helicobacter Pylori in endemic 
areas with high incidence of gastric cancer, encourage diet rich in vitamin C, fresh fruits and 
green leafy vegetables3. Early detection by screening high-risk individuals or groups, 
improvement of treatment and improving of our biological understanding of gastric 
carcinogenesis1. The highest risk is in individuals with hypochlorhydria or achlorhydria with 
extensive atrophy4.  
 
Gastric cancer is believed to arise via a multistage process that includes chronic gastritis or and 
gastric atrophy usually with Intestinal metaplasia and finally dysplasia5. Because the 
development of gastric carcinoma is slow and unpredictable, investigators have searched for pre-
malignant markers of increased risk for gastric cancer. Intestinal metaplasia sub-typed as III is 
considered an ominous precursor lesion for the intestinal form of gastric cancer as indicated in 
the preliminary data from a prospective study from three centres6. The Uganda Cancer Working 
group is mandated by the Ministry of Health to guide clinical care, standardise Oncology 
practice and promote awareness of important Oncological conditions. These guidelines serve as 
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a learning resource for health workers as well as serving the purpose of documentation of care in 
a resource-limited environment. 
 
Clinical presentation7, 8, 9, 10, 11 
Gastric cancer is difficult to diagnose early because there is usually a time lag between the onset 
of growth and the appearance of symptoms. These include but not limited to gastric distension, 
easy satiety, vomiting, anorexia, weight loss, anaemia, haematemesis, tiredness and weakness. 
Epigastric pain with lack of periodicity and non-responsiveness to treatment is a late feature. 
The patients may be conveniently grouped into five categories. 
Group I. New dyspepsia after 40 years; with indigestion and no past history suggestive of PUD.  
Group II. Insidious: tired, weak and 3As- anaemia anorexia asthenia 
Group III. Obstruction; dysphagia fullness belching and vomiting 
Group IV. Lump in epigastrium palpable in about 30% of patients with cancer of the stomach. 
Group V. Silent but presents with ascites, jaundice, Krukenberg tumours, Trousseaus’ and  
                 Trossier’s sign. 
 
The above can be rearranged into 2 categories:  Early symptoms: Group 1 and Late 
symptoms: Group II – V. 
For purposes of  ‘catching’ cancer of the stomach early, we consider new dyspepsia after the age 
of 40 and patients (irrespective) of age presenting with longstanding history of dyspepsia to be 
investigated for cancer of the stomach. (UGI endoscopy or barium contrast Studies. 




























        Previous history of dyspepsia 
 
 
First time symptoms after age of 35y   Take thorough history and physical examination          
 
 
Do scope    Routine investigations done to exclude Hepatic, Pancreatic and  
     Gall bladder diseases  
                                                            
                                                                                
                                                                      If no hepatobiliary disease & pancreatic diseases 
 
 
     Do H.Pylori test, if available if not give triple therapy  
       
 
                                                                                      Clarithomycin  
      Tinidazole 
      Lansoprazole (6/52) 
  
Plus dietary advice (small frequent meals, six of glasses in water in a day, not to lie down within 2 hours of eating) 
 
                      
                        If no or transient relief occurs, offer 2nd round of triple therapy (6/52) 
 
                        If no sustainable relief after 2nd round of triple therapy, scope the patient 




Screening and Diagnosis12,13,14,15,16 
 
Routine screening for gastric cancer is currently not practiced in Uganda. However, the 
following screening procedures may be carried out in some specialized clinics for asymptomatic 
patients seeking medical check ups. 
• Upper GI endoscopy  
• Double contrast barium meal 
Diagnosis 
Upper Gastrointestinal Endoscopy 
This investigation facility provides direct visualization of gastric mucosa and allows biopsy of 
any suspicious areas, evaluation of anatomical extent of gross disease and assists in planning 
therapy. Abnormalities that indicate possible malignancy include hyperaemia, mucosal 
irregularity, ulceration and/ or a frank mass. 
A Double Contrast Barium meal 
This is a procedure in which radiographs of the oesophagus, stomach and duodenum are taken 
after ingestion of barium sulphate and a gas-forming agent by the patient. Barium meals are 
useful in the diagnosis of structural and motility abnormalities. Gastric carcinoma usually 
appears as a polyploidy, ulcerative or infiltrative lesion. However many tumours have mixed 
morphological features so that considerable overlap exists on the radiographs. The infiltrative 
carcinomas cause narrowing of the lumen and rigidity of the stomach, producing a linitis plastica 
or leather bottle appearance. 
Staging Investigations  
Patients require a full blood count, urea and electrolytes, liver function tests liver ultrasound and 
baseline chest x-ray prior to surgery. The routine use of CT scan, skeletal survey and skeletal 
scintigraphy (Bone scans) in asymptomatic patient has very low yield and does not improve 
survival or quality of life.  
Pathology 
The common histological subtypes are:  
• Adenocarcinoma 95% 
• Primary Lymphoma 
• Others: Squamous cell Carcinoma, Small cell Carcinomas, Carcnoid tumours, 
Leiomyosarcoma 
• Metastasise from Breast and Melanoma 
 
Minimum information required from biopsy specimens is: 
• Macroscopic appearance and tumour size and site (gastric mapping) 
• Localized or multicentric nature 
• Dysplasia – mild, moderate or severe 
• Histological subtype e.g. Adenocarcinoma, Squamous cell carcinoma or other more 
unusual subtypes e.g. carcinosarcoma, melanoma, Kaposi’s sarcoma. 
• Tumour grade – well, moderately or poorly differentiated. 
• Depth of penetration and involvement of adjacent structures: hence Tumour (T) stage 
• Lymph node involvement: hence Nodal (N) stage 
• Distance of tumour from resected margins. 
For endoscopic biopsies only the third to the fifty bullets apply. 






Surgery is the only treatment that has an effect on the natural history of gastric cancer, however 
this benefit is limited to patients who present with early and perhaps local disease. Most of the 
patients we see in Uganda present in the late stages. Surgery is the best method of secondary 
prevention this applies to patients with localised disease, including those with lesions confined 
to the stomach wall and those with local lymph node involvement. The lymph nodes are 
classified in relation to the primary; those with 3 cm of the primary are classified as N1, the 
second tier of nodes (N2) vary according to location of the primary, but are essentially those that 
can be removed by resection, the more distant nodes are classified as N3. Surgical resection is 
described as D1, if the N1 nodes are excised and D2 if both N1 and N2 nodes are excised. 
 
Role of surgery 
 
Diagnosis: this may be done by endoscopy examination or at an exploratory laparotomy. 
Staging: This would normally be by a combination of preoperative investigations (CXR, CT 
scan, endoscopy laparoscopy or and laparotomy. 
Palliation – with no intent to cure, mitigation of symptoms like bleeding, gastric outlet 
obstruction, though chemo-radiation should be tried first for all symptoms to palliate. 
Curative: Radical surgery for early disease. 
 
Gastric cancer surgical options  
Indications  Option 
Mucosa limited/local lesion  
N1 disease  
N2 disease  
Staging and LN biopsy  
Staging and biopsy  
Endoscopic resection  
Laparotomy surgery D1 resection  
Laparotomy surgery D2 resection 
Laparoscopic examination  
Laparotomy  
 
Types of Surgery 
D1 resection – surgical resection (partial or total gastrectomy) with N1 Node dissection 
D2 Radical resection is commonly done by dissecting the greater omentum from the transverse 
colon and mesocolon  
 
The right gastroepiploic artery is divided as it’s ongoing from the gastroduodenal artery. The 
right gastric artery is divided on the lesser curve. The lesser momentum is taken off the liver up 
to the hiatus. The pylorus is divided allowing the entire stomach to be lifted the lymph node 
dissection starts up by removing the nodes from the gastroduodenal artery and extending this up 
to its origin on the common hepatic artery to the porta hepatis. The lymph nodes are then cleared 
medially along the common hepatic artery to its origin from the celiac axis. The nodes are 
cleared from around the celiac axis and out along the splenic artery to the splenic helium; this is 
facilitated by mobilising the spleen and distal pancreas. 
 
When all these lymph nodes have been cleared, the stomach is removed. For lesions of the 
middle and upper third of the stomach, a total gastrectomy is appropriate for lesions of the 
antrum, a high partial gastrectomy leaving the spleen is appropriate (the lymph nodes at the 
splenic helium are N3 nodes for antral lesions and this type of surgery should not be considered 
if they are involved.A total gastrectomy should be reconstructed as a Roux en Y with a 60cm 
Roux to prevent bile reflux. A partial gastrectomy is best reconstructed as a polya type of 
gastrectomy. 
 
Treatment options summary 
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Stage Surgical therapy Chemo-radiation  
Stage 0 
I T15 No Mo 
II T1-2 N0-2 Mo 
III T2-3 N1-2 Mo 
IV a T3-4 N2-3 
Mo 
IV b Any To1NM1 
 
Radical resection (D1) 
Radical resection (D2) 






5FU + 20-45Gy/5Fract  
5FU + 20-45Gy/5Fract  
5FU + 20-45Gy/5Fract  
5FU + 20-45Gy/5Fract  
5FU ± 20-45Gy/5Fract  
 
Radiotherapy and Chemotherapy (Indications of Radiotherapy and chemotherapy)  
       
External beam/radiation is administered with concomitant (5FU)-based chemotherapy. This is 
indicated in; 
• Locally advanced gastric cancer which is inoperable or which occurs in technically 
inoperable patients. In this case, radiotherapy is given with palliative intent depending on 
the performance status of the patient (KPS or ECOG) 
• Patients with incomplete tumour resection, positive microscopic margin or/and positive 
lymph nodes are all managed by combined chemo-irradiation. These patients receive 
postoperative irradiation with concurrent and maintenance 5FU-based chemotherapy18.  
Radiation technique 
The treatment portals used were developed from studies looking at the patterns of failure in 
preoperative series of gastric cancer19. However, these are modified on individual basis and also 
following the guidelines for defining clinical target volume for post-operative irradiation20. 
Patients in general should have a field covering the remaining part of the stomach, surgical 
margins and clinical positive nodes. If greater than 10 – 15 lymph nodes are pathologically 
negative, then lymph nodes involvement in the treatment field is optional21. 
 
The 3-Dimensional Conformal Radiation Therapy (3-DCRT) with more than 2 fields reduces the 
toxicity to critical structures, but only accurate if the reconstruction of tumour from pre-
operative imaging is possible and intra operative tumour bed clips are used22. Parallel-opposed 
Anterior Posterior/ Posterior Anterior (AP/PA) fields are the practical arrangement in Uganda. 
In general, the average field used is 15cm x 15 cm treating with 1.8 – 2 Gy per fraction up to 
total 45 Gy23. The lead blocks are usually used where necessary to limit the dose to the above 
structures within normal limits during treatment. However its important to include celiac axis 
T12 – L1 and portal hepatic lymph nodes that are only well covered with field extending 2cm to 
the right of T11 – L124.  
Chemotherapy  
The 5FU-based chemotherapy is standard treatment in gastric cancer. 5FU has been shown to 
sensitise the cells to radiotherapy (5FU is a pyramidine analog which blocks thymidylate 
synthatase thereby blocking DNA synthesis). The 5FU has a short half-life (20 minutes) and 
therefore is better given as a continuous infusion during radiotherapy. However, it is usually 
given as a bolus with Leucovorin (Folinic acid) which potentates its activity. Therefore, all 
patients with high-risk cancer of the stomach are given 5-FU/leucovorin usually after the 4th post 
operative week (MacDonald 2001), the Full Blood Count /Liver Function Tests/Renal Function 
Tests are done and should be in normal range before chemotherapy, patients with febrile 
condition should be treated until the temperature is normal before starting chemotherapy, dose 
may be reduced if on subsequent blood results, LFTs are compromised. Pre and post medication 
with anti-emetics is important in order to reduce the side effects of the chemotherapy. Other 
chemotherapeutic agents like capecitabine (oral 5-FU), Oxaleplatin, Irinotican can be used in 
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combination or as single agents especially in the metastatic state. Appendix IV gives the  
chemotherapy dosage details.  
Side Effects of chemotherapy 
Combined chemo-radiotherapy would give more side effects than either. Common side effects 
are nausea, vomiting and diarrhoea. Palmer-foot syndrome is rare. If the side effects are severe 
or intolerable chemotherapy or radiotherapy or both should be withheld until improvement, 
usually the haematological recovery occurs in 21days. Haemopoietic growth factors may be 
useful in cases of low white cell counts  to prevent severe infection.  
Palliative Radiotherapy25 
This provides control of local symptoms. We anticipate that 50% - 75% of patients would have 
symptomatic relief of ; pain, gastric out-let obstruction relief, cessation of bleeding and biliary 
obstruction relief. The palliative benefit is more the smaller the tumour bulk is. It also works 
well if patient have a good performance status score. The best palliation is with concomitant 5-
FU. The duration of palliation varies from 4-18months23.  
Radiation dose: 20Gy divided in 5 fractions to 45Gy at 1.8Gy per fraction with or without 5-FU 
based chemotherapy, usually 6 cycles is recommended. 
 
Prognostication26, 27, 28, 29  
Pre malignant conditions 
The following conditions are considered as pre-malignant; gastric atrophy, atrophic gastritis, 
intestinal metaplasia and severe H.Pylori infection and they should be handled as suggested 
below:  
• Gastric Atrophy: Treat for H. pylori follow up with 3-6 months Endoscopic examination. 
• Intestinal metaplasia: Eradicate Helicobacter pylori, do surveillance follow up with 6-12 
months Endoscopic examinations. 
• Severe Helicobacter pylori infection: Give triple therapy and check for full recovery 
(eradication of H Pylori) and do regular Endoscopic examinations with these the risk of 
malignancy is significantly reduced. 
 
Prognostication for early and late disease  
Early lesions: Anticipate cure (see 5 year survival below) 
Late lesions: downstage with neoadjuvant chemotherapy, then surgery (see 5 year survival) 
Metastatic:  Adjacent organs, liver. Downstage with neoadjuvant chemotherapy, then reassess 
by sonographic and Laparoscopic examination) 
 
5 year Survival rates 
o Stage 0 - Greater than 90% 
o Stage Ia - 60-80% 
o Stage Ib - 50-60% 
o Stage II - 30-40% 
o Stage IIIa - 20% 
o Stage IIIb - 10%  
o Stage IV - Less than 5%. 
Conclusion 
Gastric Cancer incidence is on the increase in Uganda. The critical strategies are to understand 
the reasons why, so as to inform locally applicable interventional strategies including  
prevention. The other important strategy is to standardize clinical approach to  diagnosis and 
treatment as an endeavour for optimal utilization of available and limited  resources as well as 
impact on outcomes. 
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